FOLH1 and prostate cancer: Another study outlined how α-particle radiotherapy for metastatic castration resistant prostate cancer using [225Ac]Ac-PSMA-617 was able to overcome resistance to [177Lu]Lu-PSMA-617 β−-particle therapy [16].